<?xml version="1.0" encoding="iso-8859-1"?> 
				<rss version="2.0"> 
				<channel> 
					<title>Latest Medical/Diabetes News and Press Release – Free Medical/Diabetes RSS @ 1888 Press Release.com</title> 
					<link>http://www.1888pressrelease.com</link> 
					<description>Free Medical/Diabetes RSS. Subscribe to latest Medical/Diabetes News and press releases @ 1888 PressRelease.Com.</description> 
					<copyright>(c) 2005-2013, 1888 Press Release.com. All rights reserved.</copyright><item>
								<title>MarketResearchReports.biz Publishes Diabetes Therapeutics Market Growth in India to 2018</title>
								<link>http://www.1888pressrelease.com/marketresearchreports-biz-publishes-diabetes-therapeutics-ma-pr-452708.html</link> 
								<description>New Market Research Report Added In MarketResearchReports.Biz Database Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth.</description>				
								<pubDate>Fri, 01 Feb 2013 00:00:00 GMT</pubDate>
							</item><item>
								<title>New Phase 1 Diabetes Clinical Trial Now Enrolling at Avail Clinical Research in Central Florida; Accepting Male and Female Participants Age 30-70</title>
								<link>http://www.1888pressrelease.com/new-phase-1-diabetes-clinical-trial-now-enrolling-at-avail-c-pr-450660.html</link> 
								<description>This study is a Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety and Tolerability of a New Drug in Obese Hyperlipidemic Adults with or without Type 2 Diabetes.</description>				
								<pubDate>Tue, 22 Jan 2013 00:00:00 GMT</pubDate>
							</item><item>
								<title>Paid Diabetes Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Age 18+ with Type 2 Diabetes</title>
								<link>http://www.1888pressrelease.com/paid-diabetes-clinical-trial-now-enrolling-at-achieve-clinic-pr-445697.html</link> 
								<description>This trial is a 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naïve subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to local label of GLP-1 receptor agonist and metformin.</description>				
								<pubDate>Sun, 23 Dec 2012 00:00:00 GMT</pubDate>
							</item>
				</channel>
				</rss>